Quotient Sciences

Molecule to cure. Fast.™

Translational Pharmaceutics®

Redefining Drug Development

For almost 20 years, we've pioneered the integration of CRO and CDMO solutions. We merge operational efficiencies, scientific rigor, and clinical insights into a single program of work that is delivered under a single project manager and organization.

Enabling Acceleration

We bypass drug-development silos. Our comprehensive approach to formulation development, on-demand GMP manufacturing, and clinical testing leverages actionable data to empower successful outcomes– manufacturing and releasing drug products in less than seven days and reducing overall development timelines by up to 12 months.

Integrating Efficiency

Close integration between drug manufacturing and clinical testing enables better decision-making while reducing time and waste. Our phase-appropriate expertise anticipates and overcomes challenges to create a personalized path for your molecule.

Accelerate molecules through development by integrating traditionally siloed services.

Translational Pharmaceutics® is a disruptive approach to drug development that helps you forge your own path to success and optimize every step by redefining the complementary, interconnected relationship between drug product design, supply and clinical testing.

The Quotient Sciences Translational Pharmaceutics® platform integrates activities and adapts solutions to help you reach key milestones as quickly and efficiently as possible.

In control, on course and always one step ahead—no matter your development phase.

Benefits of Translational Pharmaceutics®

Streamlines & simplifies

vendor management & supply chain

Better decisions

based on emerging human clinical data

Timeline acceleration

by up to 12 months on average

First-in-human

Reach a pivotal clinical milestone with a phase appropriate drug product to test the safety and tolerability of your drug. When Translational Pharmaceutics is applied for your first-in-human clinical trials, you can accelerate to the clinic and see critical data faster, with heavily reduced up front investment in drug product development and supply.

Drug Product Optimization

We enable rapid formulation and optimization with clinical testing–simplifying reformulation after Phase I and beyond to manage product lifecycle, ensure continued innovation, and meet trial success. This is our RapidFACT® approach, an application of Translational Pharmaceutics® used across more than 300 programs to date.

ADME

Whether conducting human ADME for New Drug Applications (NDA) or running in parallel with Phase II Proof of Concept (POC) studies, our Synthesis-to-Clinic® integrated ADME studies are enabled by applying Translational Pharmaceutics®.

For a list of our locations visit:
quotientsciences.com/locations

UK +44 (0)115 974 9000 I USA +1-800-769-3518
Email: **info@quotientsciences.com** I Visit: **www.quotientsciences.com**

I0029-032025